Agenus announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Life Sciences to support manufacturing activities for its lead immuno-oncology programs botensilimab (BOT) and balstilimab (BAL).
The payment was activated through contracted work orders covering key chemistry, manufacturing, and controls activities as well as production tasks related to the two therapies. These activities enable Zydus to initiate commercial supply manufacturing for the programs while also expanding production capacity to support regulatory requirements tied to biologics license application and marketing authorization application readiness.
The work is also intended to increase inventory levels in anticipation of rising demand as the therapies advance through clinical development and early access programs. The manufacturing activities will support clinical trials, compassionate access programs, and potential global commercialization efforts.
The milestone represents the first operational activity between Agenus and Zylidac Bio LLC, the U.S.-based biologics manufacturing subsidiary of Zydus Life Sciences.
Agenus said it currently maintains sufficient cGMP clinical-grade inventory of BOT and BAL to support the ongoing BATTMAN Phase 3 clinical trial, the ANSM-authorized French early access program, named patient programs in select countries, and investigator-sponsored trials. The newly launched manufacturing efforts are designed to supplement this supply and ensure the company can meet increasing demand across development and access programs.
The collaboration agreement allows for up to $50 million in contingent payments tied to BOT and BAL production orders. The $20 million payment announced today is specifically allocated to manufacturing and CMC-related work, enabling Agenus to advance production capacity without additional capital expenditures affecting its cash position.
The broader partnership between Agenus and Zydus Life Sciences was first announced in June 2025 and formally closed in January 2026. The agreement provides Agenus with long-term biologics manufacturing capacity in the United States to support global development and potential commercialization of the BOT and BAL therapies.
Botensilimab is an Fc-enhanced multifunctional anti–CTLA-4 antibody designed to stimulate both innate and adaptive immune responses, targeting tumor types that traditionally respond poorly to existing immunotherapies. Balstilimab is a fully human monoclonal IgG4 antibody that blocks the PD-1 pathway, preventing interactions with PD-L1 and PD-L2.
Approximately 1,200 patients have received botensilimab and/or balstilimab across Phase 1 and Phase 2 clinical trials. The therapies are currently accessible through clinical trials and authorized early access programs in certain countries while regulatory approvals are pursued.
KEY QUOTES
“This milestone reflects our commitment to progressing BOT and BAL to regulatory approval readiness, and to support our ongoing clinical development and paid compassionate access program needs. As reimbursed access continues in France under the AAC framework and named patient programs expand in permitted countries and enrollment advances in the global BATTMAN Phase 3 trial, it is essential that we proactively align manufacturing capacity with anticipated demand. Our partnership with Zydus enables us to scale thoughtfully while maintaining capital discipline.”
Garo H. Armen, Ph.D., Chairman And Chief Executive Officer, Agenus
